Journal article

Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Cryptococcus Genus

Ferry Hagen, H Thorsten Lumbsch, Valentina Arsic Arsenijevic, Hamid Badali, Sebastien Bertout, R Blake Billmyre, M Rosa Bragulat, F Javier Cabanes, Mauricio Carbia, Arunaloke Chakrabarti, Sudha Chaturvedi, Vishnu Chaturvedi, Min Chen, Anuradha Chowdhary, Maria-Francisca Colom, Oliver A Cornely, Pedro W Crous, Maria S Cuetara, Mara R Diaz, Ana Espinel-Ingroff Show all

MSPHERE | AMER SOC MICROBIOLOGY | Published : 2017

Abstract

Cryptococcosis is a major fungal disease caused by members of the Cryptococcus gattii and Cryptococcus neoformans species complexes. After more than 15 years of molecular genetic and phenotypic studies and much debate, a proposal for a taxonomic revision was made. The two varieties within C. neoformans were raised to species level, and the same was done for five genotypes within C. gattii. In a recent perspective (K. J. Kwon-Chung et al., mSphere 2:e00357-16, 2017, https://doi.org/10.1128/mSphere.00357-16), it was argued that this taxonomic proposal was premature and without consensus in the community. Although the authors of the perspective recognized the existence of genetic diversity, the..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Duke University


Funding Acknowledgements

V. Arsic Arsenijevic reports research grants and consultation honoraria from Pfizer and received speaker fees from Astellas, Pfizer, and Schering-Plough. O. A. Cornely reports research grants from Actelion, Aramis Pharma, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, Leeds University, MedPace, Melinta Therapeutics, Merck/MSD, Miltenyi, Pfizer, Rempex, Roche, Sanofi Pasteur, Scynexis, Seres Therapeutics, and The Medicine Company, is a consultant to Achaogen, Anacor, Amplyx, Actelion, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Matinas, Menarini Ricerche, Merck/MSD, Paratek Pharmaceuticals, Scynexis, Seres, Summit, Tetraphase, and Vical, and received lecture honoraria from Astellas, Basilea, Gilead, and Merck/MSD outside the submitted work. K. Lagrou has received research grants, travel support, and lecture honoraria from Gilead, MSD, and Pfizer. J. F. Meis received grants from Astellas, Basilea, F2G, and Merck, and he has been a consultant to Astellas, Basilea, and Merck and received speaker's fees from Merck, Gilead, and United Medical. F. de Queiroz Telles Filho received grants from Gilead, MSD, Pfizer, and TEVA as a speaker, consultant, congress chairman, and for research. P. E. Verweij received research grants from Astellas, F2G, Gilead Sciences, and Merck and received honorarium for lectures from Gilead Sciences, Bio-Rad, and Merck. All other authors have no conflicts of interest to disclose.